Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Brain Behav Immun. 2009 Jul 15;23(8):1109–1116. doi: 10.1016/j.bbi.2009.07.001

Table 2.

Baseline characteristics (means and standard deviations) of patients who developed and did not develop MDD during IFN-α treatment.

MDD (n=21) no MDD (n=74) p-value
BDI-II score 10.2+/− 1.8 6.4 +/− 0.7 p<.05
Gender 71% male 66% male p=0.66
Ethnicity 76% Caucasian 90% Caucasian p=0.16
Age (years) 47.4+/− 1.5 47.3+/− 1.5 p=0.98
Weight (kg) 86.8+/− 2.9 84.4+/−2.1 p=0.59
History of mood disorder 55% 22% p<0.005
History of drug or alcohol disorder 50% 57% p=0.55